 to put up the PowerPoint, that would be great. It's been a real pleasure for Blackford and I, as we plan this, I get together, we were saying it's been in the planning stages for quite some time and it's exciting that it's actually going to be here. A couple of housekeeping things, this agenda that is in your booklet will be trying to adhere to that very strictly so that we can make sure we make it to all the different topics that we think are important. Also, by your seat you will notice a very important single sheet of paper that talks about the desiderata of Macy's and Welch, which I think is becoming sort of perhaps will be engraved in stone somewhere someday. But that is something that as we have discussions, we'll probably refer back to these different elements frequently. So keep that handy so that you can keep track during the discussion. The breakfast is over to the side. Most of you have probably figured out that the restrooms are out and to the left. This is being webcast and we know that there are a number of people that are going to be on the webcast today. So in the discussion it's going to be very important that even if you have a voice as loud as mine in which none of you do, to use your microphones which are in front of you. And there are two things related to the microphones. One is when you press it, you'll notice a red bar will come on. When you're done making your comments make sure that you turn it off again because in most cases if there are too many on then it will close out anyone else. We're going to try and, it can be sometimes difficult in a room of this size to keep track of everyone that wants to ask a question. So just make sure you get somebody's attention, either Blackford or myself or the moderators for each of the different sessions. Our moderators are all towards the end of the inner you there where hopefully we can have pretty good sight lines. I'm not going to go through the agenda too much other than to say that we will organize it around five key questions. But first of all, here's the objectives for this meeting. Convening key thought leaders. So if you're here congratulations on being promoted to a key thought leader, you can add that to your CV. In genomic implementation and application of clinical decision support and what we really want to do today is to compare our current assessment of the state of genomic clinical decision support with what we may envision as an ideal state and then try and define gaps and strategies to close those gaps. We want to identify and engage a U.S. and international health IT initiatives that could support our recommended strategies and then define a prioritized research agenda for genomic clinical decision support. And our key questions are going to be is clinical decision support an essential element in the successful implementation of genomic medicine? And I think to some degree that's a perhaps a rhetorical question for the group that's convened around the table here. So we sort of answered, that was asked and answered to some degree, but some of the questions that underlie that is genomic clinical decision support, does it differ significantly from other types of decision support? And if so, what are the key differences? What is the ideal state and how can the impact be defined and measured? And so this is going to be in the purview of our keynote speaker, Dan Macy's, who will get us off to a great start in just a couple of minutes. We will then have three sessions that are going to be primarily discussion around three different issues that we identified as being fundamental. What are data issues that impact genomic CDS? How do we manage knowledge for genomic CDS? And what are the implementation issues surrounding genomic CDS? And you'll see in the agenda that each of those has a separate breakout discussion. Now it's not to say that there's no relationship between these, but I think what we wanted to do is to focus so that we can derive some information that would be of utility for what we're going to be doing tomorrow, which is to really spend our half day together to identify and prioritize a potential research agenda for genomic clinical decision support. So what I want to do in the last little bit of the introduction here is to very quickly go around the room and have everybody introduce themselves. So basically this is name, rank, and serial number. So give me your name and where you're from and for those of you, I think everybody knows me, but just in case, I'm Mark Williams. I'm the director of the Genomic Medicine Institute at Geisinger Health System, and we'll do the outer you. Good morning, Blackford Middleton from Vanderbilt and let me add my welcome to Marks. Thanks everybody for coming and it looks like it'll be exciting day and a half. Kirkwell-Helmsen, UNC in Renzi. I'm director of bioinformatics at Renzi. Luke Rasmussen, I'm a developer team leading software architect from Northwestern University. Rex Chisholm, Northwestern University. Dan Rodin, Vanderbilt. Josh Tenney, Vanderbilt. Paul Dexter, Regan Streef. Langley, Union University. Jamie Skipper, ONC. That's the office of the national coordinator for health IT. Nathan Hulse, Intermountain Health Care. Sulem, Intermountain Health Care. Brian Schertz in Laboratory of Medicine at the University of Washington. Brendan Keating, University of Pennsylvania. David Flannery from Rookin College of Medical Genetics. And Genomics. Jason Vassie Brigham in Women's Hospital. Heidi Rehm, Partners Health Care and Harvard Medical School. Sandy Aronson, Partners Health Care. Chris Shoot, Mayo Clinic. Betsy Humphrey's National Library of Medicine. Arjun Manray, Harvard Medical School. Liz Worthy, Medical College of Wisconsin. Derek Skolls, NHGRI. Jean Jenkins, NHGRI. Jillian Bell, Moffat Cancer Center. Chris Wetterstrand, NHGRI. Annie Nehouse, NHGRI. Jackie Ogis, NHGRI. Kristen Weitzel, University of Florida. James Hoffman, St. Jude Children's Research Hospital. Mark Hoffman, University of Missouri, Kansas City. Les B. Sicker, Intermerall Research Program, Genome Institute. Terry Minolio, Genome Institute. David Fentz-Tamaker, Virginia Commonwealth University. Josh Peterson, Vanderbilt. Dan Macy's, University of Washington. Jomastel, NCBI. Bob Fremeth, Mayo Clinic. Casey Overby, University of Maryland. I'm Ken Calmodo. I'm Associate CMIO at University of Utah, Co-Chair of the HL7 Clinical Discipline Support Group. I'm Brandon Welch from the Medical University of South Carolina. Suzanne Bellonson, Blue Cross Blue Shield Association. Alex Milisavvich, Molecular Human Genetics, Baylor, College of Medicine. Adam Berger, Institute of Medicine. Great, thank you all very much. I should have mentioned at the outset that this meeting is being sponsored by the NHGRI, and in particular, this is the seventh meeting that has been convened under a group called the Genomic Medicine Working Group, of which we have several steering committee members, Rex, Dan, myself. We've convened a number of meetings on a diverse set of topics that we think are important to move Genomic Medicine into the implementation space. And this is the latest of these meetings. They've been, I think, extremely interesting, have brought together a broad and diverse groups of stakeholders, and there have been a lot of really good things that have emerged from this, including several RFA is specifically related to some topics that have been developed. So, for example, the IGNITE program, which I know some of you are members of, was the direct result of one of these meetings. And even though it wasn't specifically under the auspices of the Genomic Medicine Working Group, the ClinGen project, which many of us are a part of, also came out of a large meeting of this sort. So I think this is something that has a lot of potential to really help those of us that are trying to move this field forward develop some traction. So, with that, I'm gonna turn it over to my co-moderator, Blackford Middleton, who's going to discuss the results of the survey that almost all of you filled out. I think it's one of the highest response rates of a survey I've ever seen, so thank you for that. Thanks very much, Mark.